ArticleTranslational oncology2026
CXCL9 drives lung adenocarcinoma progression and immunotherapy response via activation of the CXCR3/JAK1/STAT3 signaling pathway.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundC-X-C Motif Chemokine Ligand 9 (CXCL9) is an immune-related chemokine implicated in tumor progression and immunotherapy response. However, its biological role and regulatory mechanisms in lung adenocarcinoma (LUAD) remain unclear.
methodsPublic immunotherapy cohorts, The Cancer Genome Atlas (TCGA) pan-cancer datasets, and single-cell RNA sequencing data were analyzed to evaluate CXCL9 expression, prognostic value, and immune associations. Functional assays, including wound healing, Transwell invasion, apoptosis analysis, qRT-PCR, and Western blotting, were performed in LUAD cell lines with CXCL9 overexpression or knockdown. Xenograft mouse models were used to assess tumor growth in vivo. Pharmacological inhibition and receptor-blocking experiments were conducted to explore the involvement of the CXCR3/janus kinase 1 (JAK1)/signal transducer and activator of transcription 3 (STAT3) signaling pathway.
resultsCXCL9 was significantly upregulated in programmed cell death ligand 1 (PD-L1) immunotherapy responders and associated with immune-related signaling pathways. High CXCL9 expression correlated with poor prognosis in LUAD. Functional experiments demonstrated that CXCL9 promoted LUAD cell proliferation, migration, invasion, and resistance to apoptosis both in vitro and in vivo. Mechanistically, CXCL9 activated the CXCR3/JAK1/STAT3 signaling pathway, while treatment with the JAK1/2 inhibitor Ruxolitinib effectively reversed these malignant phenotypes.
conclusionOur findings identify the CXCL9-CXCR3/JAK1/STAT3 axis as a critical regulator of LUAD progression and immunotherapy response, highlighting CXCL9 as a potential prognostic biomarker and therapeutic target in LUAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.